Serelaxin fails to meet primary endpoints in phase 3 RELAX-AHF-2 trial
Serelaxin, a hormone with vasodilatory effects, failed to improve cardiovascular outcomes in the phase 3 RELAX-AHF-2 trial. Despite initial promising results from previous studies, serelaxin showed no significant benefit in reducing worsening heart failure or all-cause mortality.